Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MetaVia Inc. (MTVA)
Cambridge, MA, US
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Based on only 1 article — low confidence
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -6.72% | -6.72% | -20.71% | -27.92% | -85.57% | -86.82% | -85.26% | -96.01% | -96.01% | -96.01% | -96.01% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+81.2% ★ Q1'26: +80.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +360.7% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+150.4% Q1'26: +420.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.02× Q1'26: -0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 EPS Ana. |
Dec 2027 2 EPS Ana. |
Dec 2028 3 EPS Ana. |
Dec 2029 1 EPS Ana. |
Dec 2030 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
—
est: 80.00M (-100.0%)
|
—
|
—
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBITDA |
-11.76M
|
-28.79M
|
-13.69M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-11.78M
|
-28.81M
|
-13.71M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-13.97M
est: -717.77M (+98.1%)
|
-27.59M
est: -30.89M (+10.7%)
|
-12.97M
est: -15.69M (+17.3%)
|
-4.30M
-5.67M – -2.94M
+72.6% YoY
|
-4.17M
-6.21M – -2.12M
+3.1% YoY
|
-2.74M
-3.92M – -1.55M
+34.3% YoY
|
-2.11M
-2.11M – -2.11M
+22.9% YoY
|
-1.93M
-1.93M – -1.93M
+8.4% YoY
|
| SGA |
8.64M
|
7.26M
|
6.89M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-477.84
est: -1,017.84 (+53.1%)
|
-39.16
est: -43.70 (+10.4%)
|
-7.35
est: -8.89 (+17.3%)
|
-2.44
-3.21 – -1.66
+72.5% YoY
|
-2.36
-3.52 – -1.20
+3.1% YoY
|
-1.51
-2.22 – -0.88
+36.1% YoY
|
-1.20
-1.20 – -1.20
+20.9% YoY
|
-1.10
-1.10 – -1.10
+8.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-11 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-08 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-07 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-06 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-05 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-04 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-05-01 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-23 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings history not available.
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 6.2K | 0.05% |
Insider Activity
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-23 | Woodworth Marshall H | Officer | A-Award | A | Common Stock | 28,000 | 0.00 | — | 30,734 | D | ↗ |
| 2026-01-23 | Kim Hyung Heon | Director / Officer | A-Award | A | Common Stock | 32,000 | 0.00 | — | 37,545 | D | ↗ |
| 2025-08-12 | Woodworth Marshall H | Officer | G-Gift | D | Common Stock | 14,200 | 0.00 | — | 30,079 | D | ↗ |
| 2025-06-30 | Tursi James Patrick | Director | A-Award | A | Common Stock | 28,147 | 0.00 | — | 37,219 | D | ↗ |
| 2025-06-30 | Salsbury Michael | Director | A-Award | A | Common Stock | 28,147 | 0.00 | — | 45,699 | D | ↗ |
| 2025-06-30 | STRICKLAND D GORDON | Director | A-Award | A | Common Stock | 28,147 | 0.00 | — | 45,699 | D | ↗ |
| 2025-06-30 | KOVEN ANDREW I | Director | A-Award | A | Common Stock | 28,147 | 0.00 | — | 45,699 | D | ↗ |
| 2025-06-30 | Glickman Mark A | Director | A-Award | A | Common Stock | 28,147 | 0.00 | — | 37,887 | D | ↗ |
| 2025-06-30 | GROVES JASON L | Director | A-Award | A | Common Stock | 28,147 | 0.00 | — | 45,699 | D | ↗ |
| 2025-06-04 | Woodworth Marshall H | Officer | P-Purchase | A | Common Stock | 14,200 | 0.70 | 9.9K | 44,279 | D | ↗ |
| 2025-05-08 | DONG-A ST CO., LTD | 10% Owner | P-Purchase | A | Common Stock | 4,647,887 | 0.71 | 3.30M | 9,995,679 | D | ↗ |
| 2025-03-01 | Woodworth Marshall H | Officer | F-InKind | D | Common Stock | 3,417 | 1.46 | 5.0K | 30,079 | D | ↗ |
| 2025-03-01 | Kim Hyung Heon | Director / Officer | F-InKind | D | Common Stock | 2,795 | 1.46 | 4.1K | 61,004 | D | ↗ |
| 2024-11-30 | Kim Hyung Heon | Director / Officer | F-InKind | D | Common Stock | 2,867 | 2.55 | 7.3K | 63,799 | D | ↗ |
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Heon Kim Hyung | Chief Executive Officer, President & Director | 756.3K | male |
| Hyung-Heon Kim | Chief Executive Officer, President & Director | 756.3K | male |
| Marshall H. Woodworth | Chief Financial Officer | 563.0K | male |
| Mi-Kyung Kim | Chief Scientific Officer | — | — |
| Michael C. Pine | Senior Vice President of Business Development Advisor | — | male |
| Robert Homolka | Senior Vice President of Clinical Operations | — | male |
| W. Christopher Fang | Consulting Chief Medical Officer & Advisor | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MTVA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
